Saturday, November 14, 2026

Federal Reserve Rate Cycle Reaches 3.5-3.75% After 22-Month Policy Reversal

The Federal Reserve cut its benchmark rate to 3.5-3.75% by January 2026, completing a policy reversal that began in September 2024 after holding rates at their highest levels since 2001. The shift follows the most aggressive tightening cycle since the 1980s, which pushed mortgage rates above 8% and triggered a 26-month manufacturing contraction. Banks now face margin compression as deposit costs remain elevated while lending rates decline.

From our archive, published before source-traceability. How we work

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Federal Reserve Rate Cycle Reaches 3.5-3.75% After 22-Month Policy Reversal
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The Federal Reserve's benchmark rate stood at 3.5-3.75% in January 2026, down from peak levels reached in mid-2023 after a 16-month hiking campaign that began in March 2022. The central bank initiated rate cuts in September 2024, marking its first easing move in over four years.

The tightening cycle produced the sharpest borrowing cost increases in four decades. Mortgage rates exceeded 8% at their peak, pricing millions of homebuyers out of markets and freezing housing turnover. Manufacturing activity contracted for 26 consecutive months through the cycle's later stages, with rate-sensitive sectors including trucking and construction equipment facing acute pressure.

Commercial banks absorbed significant balance sheet stress during the transition. Net interest margins expanded during the hiking phase as banks repriced loans faster than deposits, but the cutting cycle reversed this dynamic. Regional banks particularly faced funding cost stickiness, with depositors demanding competitive rates even as the Fed eased policy.

Credit markets experienced volatility across the cycle. Corporate borrowers rushed to refinance floating-rate debt during the easing phase, while leveraged loan markets saw spread compression. High-yield bond issuance surged in late 2024 and early 2025 as companies locked in lower rates before potential policy shifts.

The Fed's restrictive policy achieved its primary inflation-fighting objective but created collateral damage across financial markets. Treasury yield curve inversions persisted for extended periods, historically a recession signal that complicated bank asset-liability management. Financial institutions holding long-duration securities faced unrealized losses exceeding $500 billion at the cycle's peak.

Bank executives now navigate a compressed rate environment where deposit competition remains fierce while loan yields decline. The Fed's measured easing pace—slower than previous cutting cycles—reflects concerns about reigniting inflation, leaving financial institutions in prolonged margin pressure. Commercial real estate portfolios face particular scrutiny as higher-for-longer rates stress property valuations and refinancing capacity.

Market participants expect the Fed to maintain rates near current levels through mid-2026, with further cuts contingent on inflation data and labor market stability.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· February 2, 2026
    Kevin Warsh’s Fed Will End the War on Main Street and Trucking

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com